Subscribe to RSS
Persistent Antibody Responses to SARS-CoV-2 Infection in Cancer Patients: A Single-Center Retrospective Observational StudyFunding Not applicable.
Introduction There is limited literature available regarding the prevalence and durability of immune response to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/coronavirus disease 2019 (COVID-19) in cancer patients.
Objective The aim of this study was to analyze the seroconversion rate in cancer patients recovered from SARS-CoV-2 infection.
Materials and Methods We retrospectively analyzed antibody levels and seroconversion rates in serum samples from 135 cancer patients who had recovered from SARS-CoV-2 infection. Chemiluminescent immunoassay using Roche Cobas e801 analyzer (Roche Diagnostics, Rotkreuz, Switzerland) was performed to identify Pan Ig antibody against nucleocapsid antigen. Reports of first, third, and sixth month were analyzed. Seroconversion was also compared with health-care workers (HCW) of our institute who had recovered from COVID-19 infection.
Results Seroconversion rate in cancer patients was 81.2% at 1 month, 95% at 3 months, and 94.6% at 6 months post reverse transcriptase–polymerase chain reaction positivity. There was no difference in seroconversion rate among different age groups, gender, comorbidities, severity of COVID-19 symptoms, cancer disease status, and treatment with chemotherapy. Seroconversion rate in cancer patients is comparable to HCW (90.4 vs. 96%, p = 0.82) and is durable.
Conclusion Humoral response to COVID-19 infection in cancer patients is comparable to general population and sustained. Such responses suggest that cancer patients are likely to benefit from COVID-19 vaccination.
KeywordsCOVID-19 - SARS-CoV-2 - anti-SARS-CoV-2-antibody - cancer - seroconversion - chemotherapy - India
06 August 2021 (online)
© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
- 1 COVID-19. Coronavirus Pandemic. https://www.worldometers info/coronavirus/. Accessed July 12, 2021
- 2 Liang W, Guan W, Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21 (03) 335-337
- 3 Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020; 323 (18) 1775-1776
- 4 Vabret N, Britton GJ, Gruber C. et al. Sinai Immunology Review Project. Immunology of COVID-19: current state of the science. Immunity 2020; 52 (06) 910-941
- 5 Zhao J, Yuan Q, Wang H. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020; 71 (16) 2027-2034
- 6 Pollán M, Pérez-Gómez B, Pastor-Barriuso R. et al. ENE-COVID Study Group. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020; 396 (10250) 535-544
- 7 Long Q-X, Tang X-J, Shi Q-L. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020; 26 (08) 1200-1204
- 8 WardH, CookeGS, AtchisonC, et al. Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults. The Lancet Regional Health - Europe, 2021;4:100098. ISSN 2666-7762. Available at: https://doi.org/10.1016/j.lanepe.2021.100098
- 9 Bölke E, Matuschek C, Fischer JC. Loss of anti-SARS-CoV-2 antibodies in mild Covid-19. N Engl J Med 2020; 383 (17) 1694-1695
- 10 Ibarrondo FJ, Fulcher JA, Goodman-Meza D. et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med 2020; 383 (11) 1085-1087
- 11 Gudbjartsson DF, Norddahl GL, Melsted P. et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med 2020; 383 (18) 1724-1734
- 12 prpt . Wajnberg A, Amanat F, Firpo A, et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. July 17, 2020 (https://www. medrxiv. org/ content/ 10. 1101/ 2020. 07. 14. 20151126v1)./prpt
- 13 Solodky ML, Galvez C, Russias B, et al. Lower detection rates of SARS-COV1 antibodies in cancer patients vs healthcare workers after symptomatic COVID-19. Annals of Oncology. doi:10.1016/j.annonc.2020.04.475.} DOI: https://doi.org/10.21203/rs.3.rs71560/v1}/prpt
- 14 Liu T, Zeng G, Tao H. et al. COVID-19 in Cancer Patients Research Group. Low prevalence of IgG antibodies to SARS-CoV-2 in cancer patients with COVID-19. Int J Cancer 2020; 147 (11) 3267-3269
- 15 Berglund A, Willén L, Grödeberg L, Skattum L, Hagberg H, Pauksens K. The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab. Acta Oncol 2014; 53 (09) 1212-1220
- 16 Nordøy T, Aaberge IS, Husebekk A. et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol 2002; 19 (02) 71-78
- 17 Polack FP, Thomas SJ, Kitchin N. et al. C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383 (27) 2603-2615
- 18 Folegatti PM, Ewer KJ, Aley PK. et al. Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396 (10/249) 467-478
- 19 Jackson LA, Anderson EJ, Rouphael NG. et al. mRNA-1273 Study Group. An mRNA vaccine against SARS-CoV-2 - preliminary Report. N Engl J Med 2020; 383 (20) 1920-1931
- 20 World Health Organization. Clinical management of COVID-19: interim guidance. May 27, 2020.
- 21 https://www.icmr.gov.in/pdf/covid/labs/2_SOP_for_Confirmatory_Assay_for_2019_nCoV.pdf. Accessed July 12, 2021
- 22 Roche. Elecsys® Anti-SARS-CoV-2. Package Insert 2020–07, V3.0; Material Numbers 09203095190 and 09203079190. US Food and Drug Administration https://www.fda.gov/media/137605/download. Accessed July 12, 2021
- 23 SetiaR, DograM, HandooA, et al. Performance Evaluation: Four Chemiluminescent SARS-Cov-2 Immunoassays and Rapid-Card Test in Mild Disease and Seroprevalence of SARS CoV-2 in Frontline Healthcare Workers. Int Blood Res Rev 2021;12(3):9-22. Available at: https://doi.org/10.9734/ibrr/2021/v12i330151
- 24 Muench P, Jochum S, Wenderoth V. et al. Development and validation of the Elecsys Anti-SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2. J Clin Microbiol 2020; 58 (10) e01694-e20
- 25 Nie J, Li Q, Wu J. et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect 2020; 9 (01) 680-686
- 26 Lei C, Qian K, Li T. et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat Commun 2020; 11 (01) 2070
- 27 Lumley SF, O’Donnell D, Stoesser NE. et al. Oxford University Hospitals Staff Testing Group. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med 2021; 384 (06) 533-540 DOI: 10.1056/NEJMoa2034545.
- 28 prpt . Harvey RA, Rassen JA, Kabelac CA, et al. Real-world data suggest antibody positivity to SARS-CoV-2 is associated with a decreased risk of future infection. medRxiv 2020; https://orcid.org/0000-0001-9372-9869/prpt
- 29 Houot R, Levy R, Cartron G, Armand P. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?. Eur J Cancer 2020; 136: 4-6